Indication
In combination with pomalidomide and dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor, and have demonstrated disease progression on the last therapy.
Medicine details
- Medicine name:
- isatuximab (Sarclisa)
- SMC ID:
- SMC2303
- Pharmaceutical company
- Sanofi-Aventis
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- Q1 2021
- SMC meeting date:
- Q1 2021
- Patient group submission deadline:
- 02 November 2020